Loading data for OKUR — first visit, this takes a few seconds.
OnKure Therapeutics, Inc. (OKUR)
NasdaqGM: OKUR
· Real-Time Price · USD
3.58
+0.02 (0.56%)
At close: Sep 10, 2026, 3:02 PM
The price, the headline numbers and the latest news, in one place.
OnKure Therapeutics, Inc. (OKUR) Stock Price, Analysis & Data
No data available
| Bid | 3.02 |
| Market Cap | 136M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -58.7M |
| 0.00 | |
| -3.03 | |
| n/a | |
| -2.21 | |
| P/B (ttm) | 0.79 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 5.32 |
| Volume | 165,540 |
| Avg. Volume (20D) | 256,625 |
| Open | 3.62 |
| Previous Close | 3.56 |
| Day's Range | 3.51 - 3.62 |
| 52-Week Range | 2.23 - 5.38 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OKUR
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The com...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 8, 2021
Employees 45
Stock Exchange NasdaqGM
Ticker Symbol OKUR
Website https://onkuretherapeutics.com
Financial Performance
In 2025, OnKure Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -59.52M, an increase of 12.99%.
Financial StatementsEarnings Surprise
OnKure Therapeutics has released their quarterly earnings on Aug 4, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.31 exceeds estimates by 0.22, with 72.81% YoY growth.
